SCHEMBL1625513

SCHEMBL1625513

Cc1ccc2[nH]c(-c3cc(N4CCC(C(=O)NCCN5CCCC5)C4)ccc3Cl)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
TSHR P16473 2/20 0.45
RECQL P46063 2/20 0.45
NOTUM Q6P988 2/20 0.43
LMNA P02545 4/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ATR Q13535 1/20 0.39
EPHX2 P34913 1/20 0.39
GPBAR1 Q8TDU6 1/20 0.39
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPT P10636 1/20 0.38
PTGES O14684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1625167 0.96 GPBAR1 (0.43) ALDH1A1TSHRRECQLNOTUMLMNA
SCHEMBL1624935 0.96 GPBAR1 (0.43) ALDH1A1TSHRRECQLNOTUMLMNA
SCHEMBL1625450 0.95 ALDH1A1 (0.46) ALDH1A1TSHRRECQLLMNAPOLB
SCHEMBL1623983 0.93 ALDH1A1 (0.46) ALDH1A1NOTUMLMNAGAANPC1
SCHEMBL1623736 0.90 SMN1; SMN2 (0.51) ALDH1A1TSHRLMNAGPBAR1NPC1
SCHEMBL1284850 0.90 SMN1; SMN2 (0.51) ALDH1A1TSHRLMNAGPBAR1NPC1
SCHEMBL1625651 0.87 HSD17B10 (0.41) TSHRNOTUMGPBAR1NPC1SMN1; SMN2
SCHEMBL1625656 0.87 HSD17B10 (0.41) TSHRNOTUMGPBAR1NPC1SMN1; SMN2
SCHEMBL1623373 0.86 EPHX2 (0.42) ALDH1A1TSHRRECQLLMNAEPHX2
SCHEMBL1623594 0.86 CYP1A2 (0.43) TSHRLMNAGAAATRGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SHH, GLI1, SMO ALDH1A1 2448/4885TSHR 1408/4885RECQL 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.